Sigyn Therapeutics, Inc. (OTCQB: SIGY) has released a statement from CEO Jim Joyce detailing the potential of CardioDialysis, a medical device designed to reduce major adverse cardiovascular events (MACE). Cardiovascular disease remains the leading cause of death globally, and current treatments, such as LDL-C reducing statins, lower MACE by approximately 25%. In contrast, Lipoprotein Apheresis devices that filter LDL-C and Lipoprotein(a) from the bloodstream have demonstrated a 75-95% reduction in MACE, according to the American Heart Association. However, these devices have limited adoption due to complex, multi-component designs and lack of global delivery infrastructure.
CardioDialysis addresses these limitations by integrating plasma separation and therapeutic adsorption within a single device that can be deployed on existing dialysis machines. This innovation enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the entire bloodstream. The device contrasts sharply with existing technologies like the Kaneka LIPOSORBER, which requires plasma separation columns, multiple cartridges, custom tubing, a blood warmer, and various pumps and fluids. The LIPOSORBER procedure has been limited to fewer than 60 specialized apheresis centers in the United States, whereas CardioDialysis could be deployed in over 5,000 hospitals and 7,500 dialysis clinics nationwide.
CardioDialysis offers several advantages over the LIPOSORBER: it addresses a broader range of cardiovascular disease targets, processes the bloodstream with greater efficiency, and eliminates the need for replacement fluids, additional pumps, or auxiliary components. Given that 15-20% of MACE result in death, the successful clinical advancement of CardioDialysis could save thousands of lives each year. The technology is part of Sigyn Therapeutics' pipeline, which also includes ImmunePrep, ChemoPrep, and ChemoPure. For more information, visit SigynTherapeutics.com.
